Toxicokinetic assessment of methylphenidate (Ritalin®) in a 13-week oral toxicity study in dogs

Biomedical Chromatography

Volumn 18, Issue 1, 2004, Pages 45-50

  Bakhtiar, Ray ^a,b   Ramos, Luis ^a   Tse, Francis L S ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Atmospheric; Dogs; Enantioselective; Mass spectrometry; Pressure chemical ionization; Ritalin ; Toxicokinetic; Vancomycin column

Indexed keywords

LIQUID CHROMATOGRAPHY; STEREOCHEMISTRY; TOXICITY;

CHEMICAL IONIZATION; DOG; ENANTIOSELECTIVE; METHYLPHENIDATE; PRESSURE CHEMICAL IONIZATION; RITALIN; RITALIN®; TOXICOKINETICS; VANCOMYCIN; VANCOMYCIN COLUMN;

MASS SPECTROMETRY;

DEXMETHYLPHENIDATE; METHYLPHENIDATE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; ATTENTION DEFICIT DISORDER; CHIRAL CHROMATOGRAPHY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG EXPOSURE; DRUG STRUCTURE; FEMALE; LIQUID CHROMATOGRAPHY; MALE; NARCOLEPSY; NONHUMAN; PRESCRIPTION; QUANTITATIVE ANALYSIS; RACEMIC MIXTURE; SEX DIFFERENCE; STATISTICAL ANALYSIS; TANDEM MASS SPECTROMETRY; TOXICOKINETICS;

ANIMALIA; CANIS FAMILIARIS; RODENTIA;

EID: 1142299603     PISSN: 02693879     EISSN: None     Source Type: Journal    
DOI: 10.1002/bmc.290     Document Type: Article

References (28)

1. Aoyama T, Kotaki H, Honda Y and Nakagawa F. Kinetic analysis of enantiomers of threo-methylphenidate and its metabolite in two healthy subjects after oral administration as determined by gas chromatographic-mass spectrometric method. Journal of Pharmaceutical Science 1990; 79: 465-469.
2. Aoyama T, Kotaki H, Sasaki T, Sawada Y, Honda Y and Iga T. Nonlinear kinetics of threo-methylphenidate enantiomers in a patients with narcolepsy and in healthy volunteers. European Journal of Clinical Pharmacology 1993; 44: 79-84.
3. Bakhtiar R, Ramos L and Tse FLS. Quantification of methylphenidate in rat, rabbit and dog plasma using a chiral liquid-chromatography/tandem mass spectrometry method: application to toxicokinetic studies. Analytica Chimica Acta 2002; 469: 261-272.
4. 11C]D-threo and L-threo-methylphenidate in the human and baboon brain. Psychopharmacology (Berlin) 1997; 131: 71-78.
5. Elia J, Ambrosini PJ and Rapoport JL. Treatment of attention-deficit hyperactivity disorder. New England Journal of Medicine 1999; 340: 780-788.
6. Faraone SV, Biederman J, Spencer T, Wilens T, Seidman LJ, Mick E and Doyle AE. Attention-deficit/hyperactivity disorder in adults: in overview. Biological Psychiatry 2000; 48: 9-20.
7. Faraj BA, Israili ZH, Perel JM, Jenkins ML, Holtzman SG, Cucinell SA and Dayton PG. Metabolism and disposition of methylphenidate-14C: studies in man and animals. Journal of pharmacology and Experimental Therapy 1974; 191: 535-547.
8. Foley R, Mrvos R and Krenzelok EP. A profile of methylphenidate exposures. Journal of Toxicology and Clinical Toxicology 2000; 38: 625-630.
9. Gainetdinov RR, Wetsel WC, Jones SR, Levin ED, Jaber M and Caron MG. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science 1999; 283: 397-401.
10. Greenhill LL and Osman BB (eds). Ritalin: Theory and Practice. Mary Ann Liebert: Larchmont, NY, 1999.
11. Horrigan JP. Present and future pharmacotherapeutic options for adult attention deficit/hyperactivity disorder. Experimental Opininious in Pharmacotherapy 2001; 2: 573-586.
12. Kimko HC, Cross JT and Abernethy DR. Pharmacokinetics and clinical effectiveness of methylphenidate. Clinical Pharmacokinetics 1999; 37: 457-470.
13. Ludden TM. Nonlinear pharmacokinetics: clinical implications. Clinical Pharmacokinetics 1991; 20: 429-446.
14. Modi NB, Wang B, Noveck RJ and Gupta SK. Dose-proportional and stereospecific pharamcokinetics of methylphenidate delivered using an osmotic, controlled-release oral delivery system. Journal of Clinical Pharmacology 2000; 40: 1141-1149.
15. Olson H, Betton G, Stritar J and Robinson D. The predictivity of the toxicity of pharmaceuticals in humans from animal data: an interim assessment. Toxicology Letters 1998; 102/103:535-538.
16. Parkinson C and Grasso P. The use of the dog in toxicity tests on pharmaceutical compounds. Human Experimental Toxicology 1993; 12: 99-109.
17. Physicians Desk Reference, 57th edn. Thomson: Montvale, NJ, 2003; 2272-2275.
18. Srinivas NR, Quinn D, Hubbard JW and Midha KK. Stereoselective disposition of methylphenidate in children with attention-deficit disorder. Journal of Pharmacology and Experimental Therapy 1987; 241: 300-306.
19. Srinivas NR, Hubbard JW, Korchinski ED and Midha KK. Enantioselective pharmacokinetics of DL-threo-mothylphenidate in humans. pharmaceutical Research 1993; 10: 14-21.
20. Srinivas NR, Lim HK, Hubbard JW and Midha KK. Evidence that dogs do not model enantioselective pharmacokinetics of DL-methylphenidate in humans. Journal of Pharmaceutical Science 1991; 80: 707-708.
21. Teo SK, Stirling DI, Thomas SD, Hoberman AM, Christian MS and Khetani VD. The perinatal and postnatal toxicity of D-methylphenidate and D,L-methylphenidate in rats. Reproductive Toxicology 2002a; 16: 353-366.
22. Teo S, Stirling D, Thomas S, Hoberman A, Kiorpes A and Khetani V. A 90-day oral gavage toxicity study of D-methylphenidate and D,L-methylphenidate in Sprague-Dawley rats. Toxicology 2002b; 179: 183-196.
23. Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Logan J, Ding YS, Hitzemann R and Pappas N. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. American Journal of Psychiatry 1998; 155: 1325-1331.
24. Wargin W, Kilts PC, Cualtieri CT, Ellington K, Mueller RA, Kraemer G and Breese GR. Pharmacokinetics of methylphenidate in man, rat and monkey. Journal of Pharmacology and Experimental Therapy 1983; 226: 382-386.
25. Wax PM. Analeptic use in clinical toxicology: a historical appraisal. Journal of Toxicology and Clinical Toxicology 1997; 35: 203-209.
26. Weber P and Lutschg J. Methylphenidate treatment. Pediatric Neurology 2002; 26: 261-266.
27. Weng X, Ding YS and Volkow ND. Imaging the functioning human brain. Proceedings of the National Academy of Science USA 1999; 96: 11073-11074.
28. Whyte J, Vaccaro M, Grieb-Neff P and Hart T. Psychostimulant use in the rehabilitation of individuals with traumatic brain injury. Journal of Head Trauma and Rehabilitation 2002; 17: 284-299.